Google’s U.S. Antitrust Trial To Resume In September
A trial to discuss potential remedies in the U.S. antitrust case brought against Google parent company Alphabet (GOOGL) has been set for Sept. 22 of this year.The antitrust case focuses on Google’s advertising business. This April, U.S. District Court Judge Leonie Brinkema ruled that Google was liable for “willfully acquiring and maintaining monopoly power,” and that Google holds illegal monopolies in online advertising markets due to its position in-between advertising buyers and sellers.Judge Brinkema’s decision followed a ruling last summer that Google has held a monopoly in its core market of internet search.The case brought against Alphabet is viewed as the most-significant antitrust case in the technology sector since the one against Microsoft (MSFT) more than 20 years ago.The trial scheduled for September will discuss remedies for ending Google’s monopoly position in online advertisements.Alphabet is looking to avoid a break-up of its business by U.S. antitrust officials. The antitrust case comes as Alphabet faces growing competition in the artificial intelligence (A.I.) market from rivals such as Microsoft, Amazon (AMZN), and Meta Platforms (META).Alphabet’s Class A stock has declined 13% year-to-date and is trading at $164.03 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


